• Adjusted EBITDA* increased by R76 million to R84,3 million
• Debt (including the Absa IMX facility) increased by R71,2 million
• Net debt stands at R507,3 million
• Cash generated from operations increased from cash used of R7,8 million to cash generated of R45,7 million
• Biological asset value increased by 5% to R2 978 million
• Net working capital increased by 20% to R245,2 million
• Earnings per share increased from 5,64 cents to 15,86 cents
• Headline earnings per share increased from 4,67 cents to 14,31 cents
• Core earnings per share^ improved from a loss per share of 10,06 cents to a loss per share of 0,09 cents
• Net asset value per share increased from 608 cents to 623 cents
• No interim dividend has been declared for the six months ended 31 December 2024 (31 December 2023: Rnil)
* Earnings before interest, taxation, depreciation, amortisation, impairment and fair value adjustment on biological assets.
^ Core earnings are defined as basic earnings adjusted for fair value adjustments on biological assets after taxation. This is a non-IFRS® Accounting Standards measure.
ABOUT THIS ANNOUNCEMENT
This announcement is the responsibility of the directors. As the information in this announcement does not provide all of the details, any investment decision should be based on consideration of the Group’s unaudited condensed consolidated interim financial statements for the six months ended 31 December 2024, which are accessible via the following JSE cloudlink: https://senspdf.jse.co.za/documents/2025/jse/isse/YRK/Interim25.pdf and can be found on the Company’s website at: https://www.york.co.za/docs/2025/YorkInterimResults2025.pdf.